Axe Compute: From Cancer Drug Discovery to AI Infrastructure Broker
A Radical Pivot
Axe Compute Inc. (AGPU) is not your typical AI infrastructure story. Just two years ago, this company was Predictive Oncology, a drug discovery firm studying ovarian cancer and licensing AI models for biotech. In the Q1 2026 earnings call, it presented a completely different business: a broker and asset owner of GPU compute clusters, with a data center offering that includes everything from sourcing NVIDIA chips to financing the build-out. The transition is stark, and management is betting the company on it.
CEO Chris Miglino, who took the helm in February 2026, framed the pivot as a response to enterprise dissatisfaction with hyperscalers: “If you want GPUs, they tell you to get in line, 36 to 52-week wait list, and you have to take the region that the data center offers.” — Christopher Miglino, Chief Executive Officer (CEO) · 2026-05-18 Instead, Axe Compute partners with businesses to build on their terms, offering any GPU, any location, and a data sovereignty guarantee.
The Landmark Deal and the Pipeline
The centerpiece is a $260 million, 36-month contract for 2,304 NVIDIA B300s with 4.8 MW of dedicated power in a U.S. Tier 3 data center. The targeted deployment is Q3 2026, with the customer paying monthly in advance regardless of utilization. CFO Jeremy Yaukey-Witter explained that revenue recognition will bring “$21 million every 3 months” — Jeremy Yaukey-Witter, Chief Financial Officer (CFO) · 2026-05-18 once the cluster goes live. This single deal dwarfs the company’s entire historical revenue—Q1 2026 revenue was just $35,000, down 68% year-over-year as the legacy Compute Services segment barely got off the ground.
Management’s confidence rests on a pipeline they claim is “over $4.3 billion” — Kyle Okamoto, President · 2026-05-18 in total contract value across 45 prospects, with 36,000+ GPUs, 72% being Blackwell architecture. President Kyle Okamoto noted that closing just 3-4 of these deals would add hundreds of millions in incremental contracted revenue. CEO Miglino went further:
He reiterated a public target of closing around $1 billion in transactions this year.We're not the data center, but we're the company that builds and owns what's inside the data center.
The Financial Reality Check
For all the hyperbole, the numbers are still pre-revenue. The company reported a net loss of $7.7 million for Q1 2026, including a $4.3 million noncash mark-to-market loss on its Aethir token holdings. Effective net cash sits at $7 million, with digital assets (tokens) worth $20.2 million and a receivable of $15.4 million from locked tokens vesting through 2028. The balance sheet is sufficient for now, but the operating loss is real, and the revenue is almost nonexistent.
The contrast with the company’s past is unavoidable. In the 2023 call, an analyst asked about cash burn and potential dilution, and CFO Bob Myers said they were “solid certainly for moving ahead over the next year.” Now the company has a completely different cost structure, with SG&A jumping to $3 million in Q1 2026, largely from severance and professional services tied to the strategic shift.
Riding a Global Wave
AGPU is not alone in chasing AI compute. The global keyword trajectory shows themes like “High performance computing” and “AI data centers” dominating recent quarters. Recent earnings reporters—from AMAT to BABA to CSCO—all mention AI infrastructure. The company is positioning itself as a pure-play intermediary, but its Compute Reserve (a pool of tokens that can be converted to bare metal compute) is a unique twist that blurs the line between hardware and financial asset.
The key question is execution. The company has signed one big deal, but the deployment is still months away. The pipeline may be real, but as Kyle Okamoto admitted, “a pipeline is a pipeline.” The market cap is under $30 million, so even the current contract would dramatically reshape the business if it delivers as promised. However, the history of this company—once a drug discovery firm with minimal revenue—suggests investors should weigh the execution risk carefully.
In summary, AGPU has made a bold pivot from biotech to AI infrastructure, with a landmark contract and a massive pipeline. The financials are still nominal, but the potential is outsized. This is a high-risk, high-reward transformation that will be defined by whether the company can translate its pipeline into cash-generating assets.